Evidence map›Paper›PMID 37878806›Full record

ArticleBlood advances2023

Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type.

Jean-François Emile, Zofia Hélias-Rodzewicz, Benjamin H Durham, Sébastien Héritier, Malik da Silva, Komel Younas, Fleur Cohen-Aubart, Omar Abdel-Wahab, Eli L Diamond, Jean Donadieu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jean-François EmileParis-Saclay University, Versailles SQY University, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France.ORCID 0000-0002-6073-4466
Zofia Hélias-RodzewiczParis-Saclay University, Versailles SQY University, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France.
Benjamin H DurhamDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Sébastien HéritierSorbonne Université, Assistance Publique-Hôpitaux de Paris, Armand-Trousseau Hospital, Service d'Hématologie Oncologie Pédiatrique, Centre de Référence des Histiocytoses and Centre d'immunologie et des maladies infectieuses UMRS 1135, Paris, France.
Malik da SilvaParis-Saclay University, Versailles SQY University, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France.
Komel YounasParis-Saclay University, Versailles SQY University, Assistance Publique-Hôpitaux de Paris, Ambroise-Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France.
Fleur Cohen-AubartInternal Medicine Department 2, French National Referral Center for Rare Systemic Diseases and Histiocytoses, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Omar Abdel-WahabMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5456-5961
Jean DonadieuAssistance Publique-Hôpitaux de Paris, Armand-Trousseau Hospital, Service d'Hématologie Oncologie Pédiatrique, Centre de Référence des Histiocytoses, Paris-Saclay University, Versailles SQY University, Paris, France.ORCID 0000-0002-4485-146X
Julien HarocheInternal Medicine Department 2, French National Referral Center for Rare Systemic Diseases and Histiocytoses, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Molecular Pathogenesis and Therapy of Systemic Histiocytic NeoplasmsR37CA259260 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eli Lous Diamond · 2021 to 2026
$3.3M
Cellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological MalignanciesK08CA218901 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DURHAM, BENJAMIN HEATH · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA218901NCI NIH HHS L30 CA231804NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA259260
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsHumansMAP Kinase Kinase 1MutationMAP2K1 protein, humanMAP Kinase Kinase 1

Identifiers

PMID37878806
PMCPMC10698544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.